Innovent Biologics (HKG:1801) said the new drug application for its anti-cancer drug ipilimumab injection "CTLA-4" monoclonal antibody was accepted by the Center for Drug Evaluation of the National Medical Products Administration of China, according to a Monday filing with the Hong Kong bourse.
The medicine also received a Priority Review designation in combination with sintilimab as neoadjuvant treatment for resectable microsatellite instability-high or mismatch repair deficient ("MSI-H/dMMR") colon cancer. This is China's first NDA for a domestic CTLA-4 inhibitor, the filing added.
The company's share prices were down over 3% in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。